Chembio Diagnostics, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its SURE CHECK HIV 1/2 and HIV 1/2 STAT-PAK rapid test Pre-Market Applications (PMAs). The approved PMAs allow Chembio to market its rapid HIV tests to clinical laboratories and hospitals in the United States. FDA approval also allows Chembio to further expand its international marketing efforts into countries that require regulatory approval in the manufacturer's country of domicile.
Genetic Engineering News
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Biom’up’s Laparoscopic Applicator Earns New Marketing Approval
The device quickly delivers Hemoblast powder to bleeding areas in minimally-invasive surgeries.
Lawmakers Want Probe of BMS/Celgene Deal
The cancer drugs the company will acquire as part of the deal include Celgene’s blockbuster drug Revlimid.
FDAnews Device Daily Bulletin
CHEMBIO RECEIVES FDA APPROVAL FOR ITS RAPID HIV TESTS; COMPANY EXPECTS NEW MARKET OPPORTUNITIES AND REVENUE GROWTH
May 31, 2006
